September 23, 2025Frontiers in OncologyOpen Access

A network meta-analysis of the safety of systemic treatments in patients with metastatic hormone-sensitive prostate cancer

View Full Paper

Ask AI

Bookmark

Risk of grade ≥3 adverse events was lowest with apalutamide plus ADT compared to other treatments.
Comparison of safety outcomes showed that docetaxel plus ADT had significantly higher serious adverse events than apalutamide plus ADT.
Bayesian network meta-analyses were conducted based on RCTs to compare safety across multiple treatment regimens.
Variability in data reporting remains a notable consideration in evaluating treatment safety.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Network meta-analysis identifies safety outcomes in systemic treatments for metastatic hormone-sensitive prostate cancer, highlighting risk differences among therapies.

Cite This Study

Maïo et al. (2025) studied this question.

synapsesocial.com/papers/68d43d68713b0b5dfea7cfb3 https://doi.org/10.3389/fonc.2025.1468928

View Full Paper

Ask AI

Bookmark

Implication

Network meta-analysis identifies safety outcomes in systemic treatments for metastatic hormone-sensitive prostate cancer, highlighting risk differences among therapies.

A network meta-analysis of the safety of systemic treatments in patients with metastatic hormone-sensitive prostate cancer

Key Points

Discussion

Implication

Cite This Study

A network meta-analysis of the safety of systemic treatments in patients with metastatic hormone-sensitive prostate cancer

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider